{
    "root": "304dd980-5e9b-d776-e063-6394a90aa9cf",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Divalproex Sodium",
    "value": "20250314",
    "ingredients": [
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        },
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        }
    ],
    "indications": "divalproex sodium extended-release tablets indicated : acute treatment manic mixed episodes associated bipolar disorder , without psychotic features ( 1.1 ) monotherapy adjunctive therapy complex partial seizures simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1.2 ) prophylaxis migraine headaches ( 1.3 )",
    "contraindications": "divalproex sodium extended-release tablets intended once-a-day oral . divalproex sodium extended-release tablets swallowed whole crushed chewed ( 2.1 , 2.2 ) . mania : initial dose 25 mg/kg/day , increasing rapidly possible achieve therapeutic response desired plasma level ( 2.1 ) . maximum recommended 60 mg/kg/day ( 2.1 , 2.2 ) . complex partial seizures : start 10 15 mg/kg/day , increasing 1 week intervals 5 10 mg/kg/day achieve optimal response ; response satisfactory , check valproate plasma level ; full prescribing information conversion monotherapy ( 2.2 ) . maximum recommended 60 mg/kg/day ( 2.1 , 2.2 ) . absence seizures : start 15 mg/kg/day , increasing 1 week intervals 5 10 mg/kg/day seizure control limiting side effects ( 2.2 ) . maximum recommended 60 mg/kg/day ( 2.1 , 2.2 ) . migraine : recommended starting dose 500 mg/day 1 week , thereafter increasing 1,000 mg/day ( 2.3 ) .",
    "warningsAndPrecautions": "divalproex sodium extended-release tablets usp , 250 mg available white off-white , capsule-shaped , biconvex , film-coated tablets imprinted \u201c za47 \u201d one side side plain supplied follows : ndc 68001-105-00 bottle 100 tablets ndc 68001-105-03 bottle 500 tablets divalproex sodium extended-release tablets usp , 500 mg available white off-white , capsule-shaped , biconvex , film-coated tablets imprinted \u201c za48 \u201d one side side plain supplied follows : ndc 68001-106-00 bottle 100 tablets ndc 68001-106-03 bottle 500 tablets storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . dispense tight , light-resistant container . maalox \u00aeis registered trademark novartis consumer health . trisogel \u00aeis registered trademark eli lilly corporation . titralac \u00aeis registered trademark 3m pharmaceuticals .",
    "adverseReactions": "hepatic disease significant hepatic dysfunction ( 4 , 5.1 ) known mitochondrial disorders caused mutations mitochondrial dna polymerase \u03b3 ( polg ) ( 4 , 5.1 ) suspected polg-related disorder children two years age ( 4 , 5.1 ) known hypersensitivity ( 4 , 5.12 ) urea cycle disorders ( 4 , 5.6 ) prophylaxis migraine headaches : pregnant women , women childbearing potential using effective contraception ( 4 , 8.1 )",
    "indications_original": "Divalproex sodium extended-release tablets are indicated for: Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features ( 1.1 ) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1.2 ) Prophylaxis of migraine headaches ( 1.3 )",
    "contraindications_original": "Divalproex sodium extended-release tablets are intended for once-a-day oral administration. Divalproex sodium extended-release tablets should be swallowed whole and should not be crushed or chewed ( 2.1 , 2.2 ). Mania: Initial dose is 25 mg/kg/day, increasing as rapidly as possible to achieve therapeutic response or desired plasma level ( 2.1 ). The maximum recommended dosage is 60 mg/kg/day ( 2.1 , 2.2 ). Complex Partial Seizures: Start at 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response; if response is not satisfactory, check valproate plasma level; see full prescribing information for conversion to monotherapy ( 2.2 ). The maximum recommended dosage is 60 mg/kg/day ( 2.1 , 2.2 ). Absence Seizures: Start at 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day until seizure control or limiting side effects ( 2.2 ). The maximum recommended dosage is 60 mg/kg/day ( 2.1 , 2.2 ). Migraine: The recommended starting dose is 500 mg/day for 1 week, thereafter increasing to 1,000 mg/day ( 2.3 ).",
    "warningsAndPrecautions_original": "Divalproex Sodium Extended-Release Tablets USP, 250 mg are available as white to off-white, capsule-shaped, biconvex, film-coated tablets imprinted with \u201cZA47\u201d on one side and the other side plain and are supplied as follows:\n                  NDC 68001-105-00 in bottle of 100 tablets\n                  NDC 68001-105-03 in bottle of 500 tablets\n                  Divalproex Sodium Extended-Release Tablets USP, 500 mg are available as white to off-white, capsule-shaped, biconvex, film-coated tablets imprinted with \u201cZA48\u201d on one side and the other side plain and are supplied as follows:\n                  NDC 68001-106-00 in bottle of 100 tablets\n                  NDC 68001-106-03 in bottle of 500 tablets\n                  \n                     Storage\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature].\n                  Dispense in a tight, light-resistant container.\n                  Maalox\n \n  \u00aeis the registered trademark of Novartis Consumer Health.\n\n \n                  Trisogel\n \n  \u00aeis the registered trademark of Eli Lilly Corporation.\n\n \n                  Titralac\n \n  \u00aeis the registered trademark of 3M Pharmaceuticals.",
    "adverseReactions_original": "Hepatic disease or significant hepatic dysfunction ( 4 , 5.1 ) Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase \u03b3 (POLG) ( 4 , 5.1 ) Suspected POLG-related disorder in children under two years of age ( 4 , 5.1 ) Known hypersensitivity to the drug ( 4 , 5.12 ) Urea cycle disorders ( 4 , 5.6 ) Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception ( 4 , 8.1 )"
}